Glycopyrronium Bromide Martindale

Glycopyrronium Bromide Martindale is an injectable solution containing the anticholinergic agent glycopyrronium bromide; the exact strength is not specified. It is marketed in the European Union as a prescription‑only medication and is administered by intramuscular or intravenous injection for peri‑operative management.

Glycopyrronium Bromide Martindale is employed in clinical settings to control secretions and support cardiovascular stability during surgery. It is indicated for several peri‑operative purposes.

- Reduction of salivary and respiratory secretions during surgical procedures - Prevention of intra‑operative bradycardia associated with anesthesia - Adjunctive therapy in the management of peptic ulcer disease - Facilitation of endotracheal intubation by decreasing airway secretions - Use in patients where anticholinergic premedication is required to minimize reflex vagal responses

Side effects of glycopyrronium bromide may vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common: - Dry mouth (xerostomia) - Blurred vision - Tachycardia - Constipation - Urinary retention - Skin flushing

Serious: - Severe hypotension - Acute angle‑closure glaucoma - Anaphylactic reaction - Cardiac arrhythmias - Persistent urinary retention requiring catheterization

When using Glycopyrrium Bromide Martindale, clinicians should consider several safety measures to minimize risk.

- Assess baseline heart rate and blood pressure before administration - Use caution in patients with glaucoma or a history of ocular hypertension - Avoid in individuals with severe urinary outflow obstruction - Monitor for signs of excessive anticholinergic load, especially in the elderly - Adjust dose or discontinue if severe tachycardia or arrhythmias develop - Consider renal or hepatic impairment when determining duration of therapy

Glycopyrronium bromide can interact with other medications, influencing its efficacy or safety profile.

Avoid: - Other anticholinergic agents (e.g., atropine, scopolamine) that may increase anticholinergic toxicity - Beta‑blockers that could mask tachycardia - Drugs that prolong the QT interval, raising the risk of arrhythmias

Use with caution: - Sympathomimetic agents (e.g., epinephrine) that may exacerbate tachycardia - Anesthetic agents that depress cardiac function - Medications affecting renal clearance if renal impairment is present